Cannabis-based medicines and medical cannabis for adults with cancer pain

CONCLUSIONS: There is moderate-certainty evidence that oromucosal nabiximols and THC are ineffective in relieving moderate-to-severe opioid-refractory cancer pain. There is low-certainty evidence that nabilone is ineffective in reducing pain associated with (radio-) chemotherapy in people with head and neck cancer and non-small cell lung cancer. There is low-certainty evidence that a single dose of synthetic THC analogues is not superior to a single low-dose morphine equivalent in reducing moderate-to-severe cancer pain. There is low-certainty evidence that CBD does not add value to specialist palliative care alone in the reduction of pain in people with advanced cancer.PMID:37283486 | PMC:PMC10241005 | DOI:10.1002/14651858.CD014915.pub2

Source: Cochrane Database of Systematic Reviews - June 7, 2023 Category: General Medicine Authors: Winfried H äuser Patrick Welsch Lukas Radbruch Emma Fisher Rae Frances Bell R Andrew Moore Source Type: research